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Abstract
Background: Laboratory services have a central role in supporting screening, diagnosis, and
management of patients. The increase in chronic disease management in primary care for
conditions such as diabetes mellitus requires regular monitoring of patients' biochemical
parameters. This process offers a route for improving the quality of care that patients receive by
using test results as a vehicle for delivering educational messages as well as the test result itself.
Aim: To develop and evaluate the effectiveness of a quality improvement initiative to improve the
care of patients with diabetes using test report reminders.
Design: A programme of four cluster randomised controlled trials within one population of
general practices.
Participants: General practices in Newcastle-upon-Tyne, UK.
Intervention: Brief educational messages added to paper and electronic general practice
laboratory test reports introduced over two phases. Phase One messages, attached to
Haemoglobin A1c (HbA1c) reports, targeted glycaemic and cholesterol control. Phase Two
messages, attached to albumin:creatinine ratio (ACR) reports, targeted blood pressure (BP)
control and foot inspection.
Outcomes: General practice mean levels of HbA1c and cholesterol (Phase One) and diastolic and
systolic BP and proportions of patients having undergone foot inspections (Phase Two); number of
tests requested.
Trial registration: Current Controlled Trial ISRCTN2186314.
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There is broad, international agreement over what consti-
tutes high quality health care for people with diabetes [1].
In the UK (UK), this is enshrined in a National Service
Framework for people with diabetes, and a series of clini-
cal practice guidelines from the National Institute for
Health and Clinical Excellence (NICE). However, despite
this increasing clarity on desirable care, there is evidence
of suboptimal performance [2].
It is well known that guidelines do not implement them-
selves, and that active strategies are needed to enhance
their uptake. While there are a range of means for
approaching this, one that has the potential advantages of
feasibility and simplicity is the attachment of educational
messages to the results of laboratory tests ordered in gen-
eral practice.
Laboratory services have a central role in supporting
screening, diagnosis, and management of patients and
represent a significant expenditure for the UK National
Health Service (NHS). Locally, the number of general
practitioner (GP) laboratory requests is increasing by 5%
each year, and such requests currently account for approx-
imately 25% of all tests performed by the Newcastle Hos-
pitals NHS Trust. In relation to diabetes, over a six-month
period from January 2004, GP requests accounted for
35% of all Haemoglobin A1c (HbA1c) requests processed
and for 52% of all cholesterol (1,557 and 5,769 per
month, respectively). There are several factors that may
have contributed to this increase in demand (for example,
shifts in the delivery of healthcare to primary care, the
impact of clinical guidelines and protocols). Across the
UK, the recent major increase in requests for several tests
(including HbA1c and cholesterol) has been related to the
introduction of a new GP contract that ties financial
incentives to performance, particularly around chronic
disease management [3,4].
Although it is difficult to judge whether this trend repre-
sents an increase in clinically appropriate practice, it has
highlighted the need for evidence on how to influence
test-ordering behaviour and potential impact – in terms of
volume – of using test results to influence other clinical
behaviours.
Available interventions to change test-ordering-related
behaviours have not been systematically evaluated in a
NHS setting. There is one relevant systematic review of
interventions to improve test-ordering behaviour. A
review of 49 studies concluded that audit and feedback of
test-requesting patterns, educational messages, changes of
request form, and guidelines were all effective in changing
test-ordering behaviour [5]. However, the studies
reviewed were of variable methodological quality, with
only eight of 49 using randomisation. A randomised trial
by members of this group (ME, JG and NS) demonstrated
that educational reminders printed on X-ray reports
returned to GPs reduced knee and lumbar spine X-ray
requests by 20% (relative reduction) [6], and that this
effect was sustained over 12 months of the intervention
[7]. Another trial (by BC, JG and JG) indicated that
enhanced feedback of requesting rates and brief educa-
tional reminder messages, alone and in combination, are
effective strategies for reducing test requesting in primary
care [8].
All but one of these studies were concerned with either
decreasing the overall volume of tests ordered or decreas-
ing the number of inappropriate tests ordered. Less is
known about the effectiveness of the methods in increas-
ing appropriate behaviour; the one study examining this
was a trial of adding guidelines to patients' records con-
ducted in a hospital setting. Subsequent to the above
review, an NHS-based study of investigation and treat-
ment of iron deficiency anaemia found that a simple mes-
sage on a haematology test result increased the
appropriate prescription of oral iron, but did not increase
the appropriate investigation of patients [9]. The broader
evidence base on the use of educational reminders sug-
gests that they are more consistently effective compared
with other professional behaviour change strategies [10].
However, their effects may be related to the types and
complexities of targeted behaviours.
A systematic review addressing the effects of quality
improvement strategies for type II diabetes on glycaemic
control suggested that changes in the structure and proc-
ess of care are effective. However, problems with classify-
ing complex interventions and the relative lack of high
quality studies indicate the need for further work to iden-
tify effective and sustainable ways of improving diabetes
care [11]. This evaluation will focus on the effects of edu-
cational reminders on both test-ordering behaviour. Its
aims are to increase appropriate test-ordering and related
clinical practice, and to improve the outcomes of diabetes
management. A completed checklist detailing adherence
of this report to CONSORT criteria for randomised con-
trolled trials is available as Additional File 1.
Aims
1. To establish a quality improvement initiative to
improve the quality of care for patients with diabetes
involving the phased introduction of test report messages.
2. To evaluate the effectiveness of each of four test report
messages within one population of general practicesPage 2 of 6
(page number not for citation purposes)
Implementation Science 2007, 2:22 http://www.implementationscience.com/content/2/1/22Methods
Participants
All 38 general practices in Newcastle that mainly used the
laboratory services of the Newcastle Hospitals Trust
(Royal Victoria Infirmary, Newcastle General Hospital,
and Freeman Hospital) at the point of the study start date
were eligible for participation. The planned interventions
were viewed as part of intended normal service develop-
ment.
General practices received a postal invitation to partici-
pate in the study. This invitation, addressed to the practice
manager, included a study information sheet in the form
of a cover letter and two copies of a consent form. The
manager was asked to share these materials with members
of the practice team and provide signed consent if the
practice wished to participate (signed either by the senior
partner or the practice manager). This was an appropriate
level for seeking consent given that the practices would
also represent the unit of randomisation. Practices wish-
ing further details and clarification were offered a practice
visit to explain more about the study.
Following this 'opt-in' approach to gain consent from gen-
eral practices, 35 practices consented to participate; only
two declined and one practice was about to close.
Interventions
The precise details of the intervention (wording and clin-
ical content) were developed by a multi-disciplinary
group, including representatives of primary care, second-
ary care, laboratory services, and the research team. The
content of the messages is congruent with the local diabe-
tes guideline and is evidence-based. The messages give
succinct educational information regarding appropriate
patient management (Table 1). The interventions were
introduced in two phases, with Phase One demonstrating
intervention feasibility and justifying continued funding
for Phase Two.
Phase One messages are attached to electronic and paper
test reports of HbA1c. From general practice, almost all
requests for HbA1c will relate to patients with diabetes.
The messages are of two types. The first message relates to
glycaemic control, is conditional on the HbA1c level, and
gives general advice about appropriate treatment. The sec-
ond message (again on an HbA1c test result form) gives a
non-specific message relating to the treatment of hyperc-
holesterolaemia in patients with diabetes. This started in
December 2005.
Phase Two messages are attached to ACR test reports and
are also of two types. The first message relates to foot
inspection and is attached to all ACR test reports. The sec-
ond message relates to blood pressure control, is condi-
tional on the ACR level, and gives advice on target blood
pressure (BP) levels for patients with and without a diag-
nosis of microalbuminuria. This started in October 2006.
The clinical foci of the interventions (e.g., glycaemic con-
trol) described here were selected because of their clinical
importance. We also considered whether there would be
scope for measurable improvements in patient outcomes
and relevant outcome data available.
Design
This programme comprises four cluster randomised con-
trolled trials (one for each of the four interventions) with
Table 1: Conditions and content of brief educational messages attached to test reports.
Study phase Type and attachment of message Content of message
Phase One Unconditional; attached to all cholesterol 
reports
For type 2 diabetes &age ≥ 40 yrs: on simvastatin 40 mg? See [local guideline] for 
detail and exclusions
Conditional; attached to all HbA1c reports If HbA1c < 6.5%
"Within target for type 2 diabetes"
If HbA1c 6.5 – 7.0%
"For type 2 diabetes, consider increasing oral therapy"
If HbA1c 7.0–8.0%
"If type 2 diabetes: on max oral therapy, e.g., Metformin 1G BD + gliclazide 160 
mg BD?"
If HbA1c > 8.0%
"If type 2 diabetes, consider insulin if on max oral Rx, e.g., Metformin 1G BD + 
gliclazide 160 mg BD"
Phase Two Unconditional; attached to all albumin: 
creatinine ratio (ACR) test reports
Newcastle Diabetes Guideline Footcare: all patients annual review of sensation, 
pulses, footwear education
Conditional; attached to all ACR test reports If ACR above 2.5
If confirmed microalbuminuria: aim for BP < 130/80 in type 2 diabetes
If ACR below 2.5
If no microalbuminuria: aim for BP control < 140/80 in type 2 diabetesPage 3 of 6
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tant that the study uses a randomised design because there
will inevitably be other initiatives relating to diabetes that
will occur during the time of the study. It is only by using
a randomised design that any observed effects can be con-
fidently attributed to the interventions.
The availability of practice-level data used to measure per-
formance for the Quality Outcomes Framework (QOF)
allowed us to stratify randomisation. For Phase One, strat-
ification was according to both the number of diabetic
patients per practice and the QOF score (proportion of
diabetic patients achieving HbA1c of 7.4 or less). For
Phase Two, stratification was according to both the pro-
portion of patients with a record of foot examination and
the proportion of patients with a record or blood pressure
of 145/85 or less. Therefore, practices, stratified by per-
formance, were randomly allocated to each intervention
independently. Randomisations were conducted inde-
pendently by a statistician using numbers randomly gen-
erated by computer.
Phase One
In the first randomisation, practices were allocated to
receive the glycaemic educational messages or control (no
glycaemic educational messages). In the second randomi-
sation, practices were allocated to receive the cholesterol
educational messages or control (no cholesterol educa-
tional messages).
Phase Two
After nine months, practices were re-randomised and
again assigned to each of two interventions. In the first
randomisation, practices were allocated to receive the foot
inspection reminder message or control (no foot inspec-
tion reminder message). In the second randomisation,
practices were allocated to receive the blood pressure edu-
cational messages or control (no blood pressure mes-
sages).
The four randomisations allow comparisons of the sepa-
rate effects of the four educational message interventions.
The study is not powered to compare the effects of various
combinations of intervention.
Following recruitment and randomisation, two further
participating practices merged, bringing the number of
enrolled practices to 34. These practices are now receiving
the educational messages according to their respective
randomisations.
Outcomes
For Phase One, the two primary outcomes will be the gen-
eral practice mean levels of HbA1c and cholesterol. We
hypothesise that in practices receiving the glycaemic and
cholesterol messages, compared to those practices not, the
mean HbA1c and cholesterol values will be lower, respec-
tively. Secondary outcomes for Phase One include the
number of HbA1c and cholesterol tests requested (stand-
ardised for practice size) and the proportions of patients
within each practice meeting QOF targets for glycaemic
and cholesterol control.
For Phase Two, the primary outcomes will be the general
practice mean levels of diastolic and systolic BP, and pro-
portions of patients having undergone foot inspections.
We hypothesize that in practices receiving the blood pres-
sure messages compared to those practices not, the mean
diastolic and systolic blood pressure values will be lower;
and in those receiving foot inspections messages, the pro-
portions of patients receiving a foot inspection will be
higher. Secondary outcomes for Phase Two include: the
proportions of patients in each general practice within tar-
get levels for blood pressure control according to the pres-
ence or otherwise of recorded microalbuminuria (which
requires tighter BP control); the overall number of ACR
tests requested (standardised for practice size); and the
number of ACR tests requested (standardised for practice
size) for patients with and without a diagnosis of micro-
albuminuria.
Data collection
There are three main potential sources of data to assess the
effectiveness of the messages: general practice-held data;
centrally-held and publicly available QOF data; and cen-
trally-held laboratory data. We shall only use the QOF
and laboratory data if we are unable to collect practice-
held data from all or most practices. However, the plans
for all forms of data collection are discussed below.
Practice-held data
General practices routinely collect standardised patient
data that contribute to the calculation of QOF scores.
Although 'exception reporting' allows practices to exclude
patients with diabetes who consistently do not attend for
care, practice data are scrutinised for completeness by
local Primary Care Trusts (PCTs). These QOF data will be
used to measure the primary outcomes for the trial,i.e.,
practice mean levels of HbA1c, cholesterol, diastolic and
systolic BP, and proportions of patients having undergone
foot inspections. Target levels for BP control depend on
whether microalbuminuria is present. These data will also
allow us to identify the subgroup of patients with a diag-
nosis of microalbuminuria so that their levels of BP con-
trol can be determined.
Collection and processing of these data will be under-
taken on our behalf by Newcastle PCT, and all data will be
anonymised before being transferred to the research team.
Additional consent will be sought from practices for thisPage 4 of 6
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and post-intervention outcome data will be collected dur-
ing a single visit to individual practices. Data collection
periods will cover 24 month pre-intervention periods (to
provide baseline values), and up to 18 months post-inter-
vention for phase one and eight months for phase two.
Quality outcomes framework
The general practice-level data now routinely collected
and publicly reported for QOF monitoring offers a poten-
tial and easily accessible means of monitoring and evalu-
ating the impact of quality improvement strategies.
Although these measures may be less sensitive to change
than the main study outcomes, any impact will increase
the utility of the intervention to general practices (i.e., if it
is seen to improve scores and hence incomes for prac-
tices). We will collect relevant QOF data for the time peri-
ods corresponding to the study intervention periods.
Laboratory-held data
Because the laboratory currently cannot routinely identify
patients with diabetes, we will use HbA1c test requests as
a marker for patients with diabetes. From general practice
almost all requests for HbA1c relate to patients with dia-
betes. We will identify cholesterol test requests carried out
in patients who have had HbA1c tests. This data linkage
activity will be done as a manual interrogation of the lab-
oratory computer information system by an NHS labora-
tory scientist. All data are anonymised at source before
being transferred to the research team.
Data on the numbers of HbA1c and cholesterol tests will
be extracted from the main laboratory computer informa-
tion system for each referring general practice for a period
of 12 months before (to provide baseline values). Out-
come data for these variables will be collected following a
period of 18 months after the start of the phase one inter-
ventions.
Assessment of intervention fidelity
We will contact different practices in each of the four
study arms over regular intervals to check whether prac-
tices are receiving their randomly allocated messages, and
that the messages are continuing over the intervention
period as planned.
Sample size
The sample size calculations, based on methods described
by Donner et al. [12], were undertaken using a pro-
gramme developed by Campbell et al. [13]. They were
originally based upon the following assumptions: The
study would be carried out in a population of 39 practices
with an average number of 62 patients per practice
(patients with diabetes whose care is undertaken either by
the general practice or shared between the general practice
and hospital); a significance level of 5%; 80% power; for
binary outcomes (e.g., was a test ordered?) the intraclass
correlation coefficient (ICC) equals 0.2; and for continu-
ous outcomes (e.g., mean HbA1c) the ICC = 0.05.
Under these assumptions, we will be able to detect a 20%
improvement (from 55% to 75%) in a binary outcome
measure and an effect size of 0.24 in a continuous out-
come measure. This represents a change of 0.35% in mean
HbA1c, 0.26 mmol/L in mean cholesterol, 4.78 mmHg in
mean systolic blood pressure and 2.45 mmHg in mean
diastolic blood pressure. These were based on estimated
standard deviations of 1.45, 1.07, 19.9 and 10.2, respec-
tively, from a recent trial of a diabetes recall and manage-
ment system for primary care [14].
When we subsequently extended the evaluation, we kept
the same basic assumptions for the power calculation,
with the exception that the number of participating prac-
tices had fallen to 34. We will be able to detect a 21%
improvement (from 55% to 76%) in a binary outcome
measure and an effect size of 0.25 in a continuous out-
come measure. This represents a change of 0.36% in mean
HbA1c, 0.27 mmol/L in mean cholesterol, 4.98 mmHg in
mean systolic blood pressure and 2.55 mmHg in mean
diastolic blood pressure.
The statistical power for the evaluation of the foot exami-
nation message is problematic. Our original assumptions
during the planning of Phase Two had been based on pre-
intervention compliance much lower than the 90% sug-
gested by recently available QOF data. Based on the pre-
ceding assumptions (including 34 practices), we have
only 58% power to detect a 5% improvement (from 90%
to 95%).
Statistical analysis
For Phase One, the dependent variables will be the last
recorded HbA1c and cholesterol levels. For Phase Two,
the dependent variables will be the last recorded levels of
diastolic and systolic BP and the proportions of patients
with recorded foot inspections.
Subjects included in the analysis will be all those patients
registered with each practice with a diagnosis of diabetes
whose care is undertaken either by the general practice or
shared between the general practice and hospital. Where
multiple observations (e.g., of cholesterol levels) are avail-
able for one subject within a pre- or post-intervention
period, we will use the most recent observation. Data will
be analysed using multilevel modelling with patients
nested within practices. Within practices, a binomial error
structure will be assumed for binary variables and a nor-
mal error structure for continuous variables. In each case,Page 5 of 6
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effect with a Gaussian distribution.
The dependent variable will be the outcome measure cor-
responding to the period after the intervention. Where
appropriate, the pre-intervention value of the variable will
be included in the model as a covariate. The difference
between practices receiving a particular intervention and
those not receiving that intervention will be included as a
fixed effect.
We will assess any change in blood pressure across all par-
ticipants but fit a different effect for patients with micro-
albuminuria at baseline. This analysis will allow us to
determine whether the messages had a differential effect
according to whether microalbuminuria is present.
The revised study can be conceptualised as four separate
trials of different education messages with each message
being targeted at a specific outcome. The first step in the
analysis will be to obtain estimates of the effect of each
intervention on the primary outcome with which it is
associated. The second step will be to estimate the effect of
each intervention on the secondary outcomes with which
it is associated. The final step will be to investigate
whether an intervention has had a secondary effect on
outcomes other than those targeted. The interventions
have been introduced two at a time; allocation of practices
to interventions within each pair was according to a two-
by-two factorial design. Estimates of the secondary effects
of an intervention will be based on a main effects model
that also includes the effect of the intervention (intro-
duced at the same time) which targets that particular out-
come.
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